Science is accelerating. The systems meant to deliver it are learning to move more slowly.
Tomorrow in Dublin, at the western edge of Europe, the International Alliance for Personalised Medicine convenes Innovation and Securing Patient Access to Personalised Medicine. The purpose is not simply to discuss another generation of technologies. It is to bring patients, clinicians, researchers, industry and policymakers into the same room and ask a more uncomfortable question: who takes responsibility when innovation exists, but access does not?
We speak constantly about regulation. Less often about self-regulation, institutional behaviour and the way power can disappear inside procedure. Healthcare is genuinely complex. Biology is complex. Evidence is complex. Regulation is complex.
But there is also, at times, a conspiracy of complexity where none need exist.
A diagnostic exists. The evidence exists. The clinician understands its value. Yet the test is not reimbursed, the pathway is fragmented, the budget belongs to another department, or responsibility has been divided so many times that nobody quite owns the decision. That is not scientific complexity.
That is complexity being used to avoid a choice.
Consider 300 patients entering a clinical trial because science does not yet know the answer. One hundred and fifty may receive the new intervention; another 150 may receive placebo, control treatment or standard care.
That uncertainty can be scientifically and ethically necessary. But it should never become emotionally invisible. If the intervention ultimately proves transformative, some participants will discover that they spent precious time on the side of the experiment that could not offer that benefit. Nobody knew the answer beforehand—that is precisely why the trial existed.
Yet there remains something unsettling about it. They were not on the wrong side of science. They were on the wrong side of what science had not yet learned.
In almost any other safety-critical field, exposing large numbers of people to materially different outcomes would create an overwhelming demand to reduce that period of uncertainty as quickly as possible. Medicine has developed an essential language for managing it: randomisation, endpoints, controls, confidence intervals and statistical significance.
We need that language. But we must never allow it to obscure the individual.
A patient is not an endpoint. This is why the discussion in Dublin around a European health innovation funding mechanism matters. The programme places financing alongside diagnostics, liquid biopsy, digital pathology, evidence generation and access.
An Innovation Fund should not simply finance the next discovery. Europe is already exceptionally good at producing science.
The greater challenge is financing the journey from discovery to implementation: validation, diagnostics, infrastructure, reimbursement, workforce readiness and adoption. And that is where IAPM must operate, as the bridge between what science makes possible and what policymakers make real.
Because regulation is necessary. Evidence is necessary. Trials are necessary. But none of them removes responsibility.
And in a world already running warm—politically, economically, environmentally and socially, we have less room for systems that manufacture complexity around decisions we increasingly understand.
From the edge of Europe in Dublin, the question becomes very simple: If the science is ready, who has the power and who accepts the responsibility—to ensure the patient is not left waiting for history to catch up?
In this issue
- Europe rewrote the medicine clock. The patient is still watching it: The Council has adopted a major pharmaceutical reform; Parliament must still complete the law.
- Two billion dollars bought a seat beside the cancer trial: AstraZeneca’s investment in Summit is a bet on combining targeted drug delivery with immunotherapy.
- A broken transporter finally has a way around it: The first approved treatment for MCT8 deficiency addresses its dangerous excess of circulating thyroid hormone.
- The fourth year asked the gene therapy a harder question: A Huntington’s treatment still shows signs of benefit, but its prespecified four-year measure missed statistical significance.
- The eye clinic stopped counting visits and started following people: Kenya is building a system to see where patients disappear along the care pathway.
- The tap went dry. The clinic kept receiving patients: Havana’s water and power failures have become a direct threat to infection control.
- Dengue arrived at an already crowded hospital: Bangladesh begins October with a worsening outbreak alongside a devastating measles crisis.
- The forecast is now a medical responsibility: WHO says organisers of mass gatherings must plan for heat before the crowd arrives.
| This is not another health news digest. It’s a twice-weekly readout of where evidence meets power and where power must turn into action. |
Europe rewrote the medicine clock. The patient is still watching it
The Council of the EU adopted its position on the pharmaceutical package on 28 September. The reform sets eight years of regulatory data protection for new medicines, followed by one year of market protection, with possible extensions linked to specified forms of innovation and unmet medical need. It also gives member states a tool to require adequate supply of protected medicines and creates an incentive for priority antibiotics. The European Parliament must still adopt the texts before the rules can enter into force. (Council of the EU)
This is where Europe has chosen to put its political weight: rewarding development while trying to make medicines available across the Union. The protections can be counted precisely. Their effect on a patient waiting for a medicine in a particular health system cannot. The test is whether supply obligations, faster generic entry and national access decisions make the new clock run differently for the people outside Brussels.
Two billion dollars bought a seat beside the cancer trial
AstraZeneca has agreed to invest $2 billion in Summit Therapeutics and to test Summit’s PD-1/VEGF bispecific antibody, ivonescimab, alongside AstraZeneca’s antibody-drug conjugate targeting Claudin-18.2 in gastrointestinal cancers. The companies plan broader combination research, but the first collaboration is a clinical-development agreement, not evidence that the two investigational medicines work better together. (AstraZeneca)
The transaction shows how oncology strategy is being assembled before the decisive combination trials are run. One company has a way to deliver a drug to a tumour target; the other controls rights to an immunotherapy it hopes can change the tumour’s response. Capital can bring those programmes together quickly. The clinical question still belongs to patients in the trial, and the eventual access question will belong to health systems asked to pay for the result.
IPM News
Dublin has the room. Now it needs decisions.
Tomorrow, 2 October, the International Alliance for Personalised Medicine and the Irish Patients’ Association will bring policymakers, patients, clinicians, researchers, regulators and industry together at RCSI University of Medicine and Health Sciences, 123 St Stephen’s Green, Dublin. Held during the Irish Presidency, Innovation and Securing Patient Access to Personalised Medicine asks why a scientific success can travel through research and approval, then stall before reaching routine care. (IPM conference announcement and agenda)
The discussions will move from a proposed European health innovation funding mechanism to liquid biopsy, digital pathology, global trials and local access. The point is to put diagnostics, evidence, reimbursement and implementation in the same conversation as the treatment itself. If you will be in Dublin, register here and join us.
A broken transporter finally has a way around it
The FDA has approved tiratricol, marketed as Emcitate, for peripheral thyrotoxicosis in people with MCT8 deficiency, also known as Allan-Herndon-Dudley syndrome. The inherited disorder disrupts the transport of thyroid hormone into the brain while excess hormone circulates elsewhere in the body, placing strain on the heart and metabolism. Tiratricol can enter cells without relying on the faulty transporter. In two studies, treatment reduced excess circulating thyroid hormone and improved related cardiovascular and metabolic measures. (US Food and Drug Administration)
For families who have had no FDA-approved option, that is a real change. It is also important to say exactly what has changed: this approval treats the peripheral thyroid-hormone problem. It does not establish that the medicine reverses the condition’s severe neurological effects. Precision medicine earns trust when it can explain both the mechanism it has reached and the part of a disease it has yet to reach.
The fourth year asked the gene therapy a harder question
UniQure’s experimental Huntington’s gene therapy, AMT-130, showed a 44% slowing of progression on its prespecified composite measure at 48 months among 12 high-dose patients compared with an external control group. That difference did not reach statistical significance. A separate measure of day-to-day functional capacity showed a 61% slowing, with a nominally significant result. The company says missing data in the comparison group may have made the four-year treatment effect look smaller. (uniQure’s 48-month data release)
There is a genuine signal here, and a genuine argument over its strength. The earlier 36-month analysis, which underpins the company’s submitted US application, looks more favourable; the four-year comparison is smaller, later and harder to interpret. People living with Huntington’s need a treatment that changes the disease. They also need a regulator able to distinguish an encouraging pattern from an answer sturdy enough to survive longer follow-up.
The eye clinic stopped counting visits and started following people
Kenya is working to introduce case-based reporting for eye care across 11 counties in its western Lake Basin region. Instead of recording only how many consultations or operations took place, the system is designed to follow an individual from assessment through referral, treatment, surgery and follow-up. The Ministry of Health is leading the work with WHO and partners, adapting standard indicators to local clinical and digital systems. (World Health Organization)
A service can report a busy month and still lose the patient between screening and surgery. Following the journey should make waiting times, missed referrals and outcomes more visible. This is an implementation effort, with the reporting system still being established. Its political promise is accountability: a health system that can see where care stops has fewer places to hide the gap.
The tap went dry. The clinic kept receiving patients
In Havana, prolonged power cuts and water shortages are making basic hygiene difficult for households and health workers. Reuters reported that one resident’s building had received no running water for two months before a brief supply returned. A nearby nurse described treating people during a wave of illness in a clinic where water was sometimes unavailable for handwashing. Cuban authorities have warned of spreading viral illnesses, while the UN estimates that water shortages affect around 3.5 million people across the island. (Reuters reporting from Havana)
No amount of clinical sophistication substitutes for a working tap between patients. Ageing infrastructure, power failures and the fuel blockade are converging in the place where public health is most physical: clean hands, safe water and a functioning clinic. Health policy can debate resilience for years. A nurse discovers whether it exists at the sink.
Dengue arrived at an already crowded hospital
Bangladesh recorded 148 dengue deaths in September, its highest monthly toll this year, and entered October with warnings that infections could rise further. The health ministry’s figures cited by Reuters put the year’s dengue toll at at least 245 deaths and 79,620 hospital admissions. Hospitals are facing that pressure while the country also responds to a major measles outbreak. One recently discharged dengue patient described being fortunate to get a bed. (Reuters reporting from Bangladesh)
A mosquito does not check whether the infectious-disease ward is full. Recent rain may sustain transmission into October, and specialists warn that fogging alone cannot remove the breeding sites driving spread. The immediate work is local and unglamorous: surveillance, removing standing water, reaching missed children with vaccination, and keeping hospitals able to manage two outbreaks at once. The cost of prevention is visible in a budget. The cost of neglect arrives looking for a bed.
The forecast is now a medical responsibility
WHO has issued guidance for preventing heat-related illness at major sporting, religious and cultural gatherings. Its evidence review covered nearly half a million medical encounters, including more than 22,000 heat-related illnesses. Where on-site medical systems were well organised, studies found that more than 90% of patients could be treated at the venue. WHO calls for heat-risk assessment, safe drinking water, cooling, schedule changes, crowd management and protection for workers as well as attendees. (World Health Organization)
For years, a dangerous forecast could be treated as background information and a medical team as the fallback plan. WHO is moving responsibility earlier, into the decisions about the venue, the timetable and the people hired to run it. That is a useful definition of preventive health policy: do the difficult organising before anyone needs a stretcher.
The October watch | 1–7 October
| 1 October | Influenza’s next move: |
| The FDA vaccine advisory committee discusses strain selection for 2027 Southern Hemisphere flu vaccines. |
| 1–2 October | Health policy at Gastein: |
| The European Health Forum Gastein closes with discussions spanning pharmaceutical reform, patient access, cancer policy and Europe’s health security. |
| 2 October | Dublin: |
| Innovation and Securing Patient Access to Personalised Medicine puts the route from evidence to patient benefit on the table at RCSI. |
| 5–6 October | The cancer evidence test: |
| A CDDF–EORTC workshop in Brussels and online examines how cancer-drug trials generate evidence for health technology assessment and access decisions. |
| 5 October | Cell and gene therapies: |
| EMA and the International Society for Cell and Gene Therapy hold their first bilateral meeting. It is by invitation; watch for the regulatory questions it raises. |
| 6–7 October | Rare and advanced therapies: |
| EMA’s orphan-medicines committee meets from 6 October, and its advanced-therapies committee begins on 7 October. These are committee meetings, not promised approval announcements. |
Follow the last-mile conversation!
IPM Alliance tracks the decisions, bottlenecks and implementation gaps shaping personalised medicine access. Follow us for briefings, events, policy signals and practical insights from across regions and disease areas.
We want to hear from you
When a patient becomes eligible for personalised care, where does the system most often lose them: identification, testing, referral, reimbursement, delivery capacity or equity?
Know someone who should be reading this?
IPM Brief is built for people working where science, policy and patient access collide. If one colleague would find this useful, forward it to them and help bring them into the conversation.
International Alliance for Personalised Medicine
Avenue de l’Armée / Legerlaan 10, 1041 Brussels, Belgium
